March 18 (Reuters) - Ocugen Inc :
* OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019
* OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEAR
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments